Deticene review

Deticene, an alkylating agent, is a medication used for the treatment of cancer and is administered either through intravenous infusion or injection.

Deticene is available under the brand names DTIC-Dome, DIC, DTIC, and Imidazole Carboxamide. This medication is recommended for patients with metastatic malignant melanoma, fibrosarcomas, soft tissue sarcomas, rhabdomyosarcoma, neuroblastoma, islet cell carcinoma, and carcinoma of the thyroid.


Deticene can be administered intravenously through cannula at the back of a hand or through a thin plastic tube placed beneath the skin and into a vein close to the collarbone. It can also be administered through a thin tube placed into a vein of the PICC line, or by infusion via the cannula. The infusion normally takes anywhere from 30 minutes to 2 hours.

The length of Chemotherapy and number of treatment cycles depend on the type of cancer being treated. It is normal for Deticene to be taken with other chemotherapy medications.

The amount of Deticene prescribed depends on numerous factors that include the overall health of the patient and the type of condition being treated.


Patients should know that their reaction to Deticene might differ from the reactions of other patients. Some patients may experience minimal side effects, while others may experience more.

Patients taking Deticene may feel sick while taking the medication. Nausea and vomiting may become apparent a couple of hours after administration of the medicine and can last for several days. Doctors usually prescribe anti-emetic medications to reduce these symptoms.

Deticene can also lessen the bone marrow’s production of white blood cells. This would result in a patient becoming more susceptible to infections. This side effect can become apparent a week after administration of Deticene. After a few weeks, the number of white blood cells will steadily increase.

Deticene can also lessen the number of platelets in the body, which leads to unexplained bleeding or bruising. Patients may suffer from blood spots, nosebleeds, and bleeding gums as a result.

Patients taking Deticene may also experience a decreased production of red blood cells or anemia. This usually makes the patient feel exhausted and breathless.

Deticene may also lead to a loss of appetite and abnormal hair loss. Other rare side effects include diarrhea, sensitivity to sunlight, pain at the injected area, sore ulcers, and flu-like symptoms.

Patients should immediately inform their doctor if they experience any of these side effects or if they persist or worsen.


Before taking Deticene, patients should inform their doctor of any and all medications that they are taking, whether prescription, non-prescription or herbal medications. Patients should also avoid medications containing aspirin unless given approval by doctors.

It is not safe for patients to take any sort of immunization while taking Deticene.


Deticene may affect the fertility of the patient. Patients should discuss this with their doctor before taking the medication. It is not advisable for patients to breast feed while taking Deticene since it may be passed on to the infant.

Deticene has the following structural formula:

Chemical structure of deticene

 Molecular formula of deticene is C6H10N6O
 Chemical IUPAC Name is 5-dimethylaminoazo-3H-imidazole-4-carboxamide
 Molecular weight is 182.183 g/mol
 Deticene available : 100mg tablets and 200mg tablets

Generic name: Dacarbazine

Brand name(s): Biocarbazine R, Dacarbazino, Dacarbazinum, Imidazole Carboxamide

  Your Deticene review